$14.44
0.36[2.56%]
At close: Apr 18
$14.44
0[0.00%]
After Hours: 4:00PM EDT
Nurix Therapeutics
(NASDAQ:NRIX)Nurix Therapeutics Stock (NASDAQ:NRIX), Analyst Ratings, Price Targets, Predictions
Nurix Therapeutics Inc has a consensus price target of $25.83, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Baird, and Needham on April 11, 2024. With an average price target of $26.33 between RBC Capital, Baird, and Needham, there's an implied 82.36% upside for Nurix Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Baird
Needham
Morgan Stanley
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Nurix Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 59.28% | RBC Capital | Gregory Renza | $22 → $23 | Maintains | Outperform | Get Alert |
| 04/11/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 73.13% | Baird | Joel Beatty | $24 → $25 | Maintains | Outperform | Get Alert |
| 04/11/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | $31 → $31 | Maintains | Buy | Get Alert |
| 03/11/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | -30.75% | Morgan Stanley | Terence Flynn | $9 → $10 | Maintains | Equal-Weight | Get Alert |
| 02/20/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 31.58% | HC Wainwright & Co. | Robert Burns | $35 → $19 | Maintains | Buy | Get Alert |
| 02/16/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 38.5% | Wells Fargo | Derek Archila | $23 → $20 | Maintains | Overweight | Get Alert |
| 02/16/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 52.35% | RBC Capital | Gregory Renza | $24 → $22 | Maintains | Outperform | Get Alert |
| 02/16/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/02/2024 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 11/02/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 66.2% | RBC Capital | Gregory Renza | $29 → $24 | Maintains | Outperform | Get Alert |
| 10/13/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 100.83% | RBC Capital | Gregory Renza | $30 → $29 | Maintains | Outperform | Get Alert |
| 10/13/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 142.38% | HC Wainwright & Co. | Robert Burns | $33 → $35 | Maintains | Buy | Get Alert |
| 09/07/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 114.68% | Needham | Gil Blum | → $31 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | NRIX | Buy Now | Nurix Therapeutics | $14.44 | 128.53% | HC Wainwright & Co. | Robert Burns | $53 → $33 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Nurix Therapeutics (NRIX)?
The latest price target for Nurix Therapeutics (NASDAQ: NRIX) was reported by RBC Capital on April 11, 2024. The analyst firm set a price target for $23.00 expecting NRIX to rise to within 12 months (a possible 59.28% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nurix Therapeutics (NRIX)?
The latest analyst rating for Nurix Therapeutics (NASDAQ: NRIX) was provided by RBC Capital, and Nurix Therapeutics maintained their outperform rating.
When was the last upgrade for Nurix Therapeutics (NRIX)?
The last upgrade for Nurix Therapeutics Inc happened on May 31, 2022 when Wells Fargo raised their price target to $25. Wells Fargo previously had an equal-weight for Nurix Therapeutics Inc.
When was the last downgrade for Nurix Therapeutics (NRIX)?
There is no last downgrade for Nurix Therapeutics.
When is the next analyst rating going to be posted or updated for Nurix Therapeutics (NRIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nurix Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nurix Therapeutics was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Nurix Therapeutics (NRIX) correct?
While ratings are subjective and will change, the latest Nurix Therapeutics (NRIX) rating was a maintained with a price target of $22.00 to $23.00. The current price Nurix Therapeutics (NRIX) is trading at is $14.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.